FCPM III SERVICES B V
Q3 2026 Form 13-F

NAARDEN
CIK 0002013410 · Institutional investment manager
Consolidated report · includes 3 managers since Q4 2023
$1.1B Reported Value Total
Reported value
$1.1B
Quarter over quarter
-26.5%
Holdings
15
Top-10 concentration
96.4%

Filing Structure

Reports holdings for

  • Forbion Growth Management B.V. (not a 13F filer in our records) · File #028-24009 · since Q4 2023
  • Forbion IV Management B.V. (not a 13F filer in our records) · File #028-24010 · since Q4 2023
  • Forbion Growth Management III B.V. (not a 13F filer in our records) · File #028-26443 · since Q1 2026 · declared by one filing
  • Forbion Growth Management III B.V. (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
  • Forbion Growth Management II B.V. (not a 13F filer in our records) · File #028-25150 · Q1 2025 – Q3 2025 · declared by one filing
  • Forbion Growth Management II B.V. (not a 13F filer in our records) · Q4 2024 – Q4 2024 · declared by one filing

Key People

Named on the latest Form 13-F filing — not necessarily an owner
M.a. Van Osch And G.j. Mulder
Directors

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $1.1B
Positions 15
Change in reported value +41.4%
New positions 4
Exited positions 0
Position turnover 26.7%
Top-10 concentration 96.4%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
15 $1.1B
Q2 2026 13F
Filed Aug 14, 2026
11 $750.4M
Q1 2026 13F
Filed May 15, 2026
10 $722.2M
Q4 2025 13F
Filed Feb 17, 2026
10 $762.9M
Q3 2025 13F
Filed Nov 14, 2025
9 $500.4M
Q2 2025 13F
Filed Aug 14, 2025
8 $369.2M
Q1 2025 13F
Filed May 15, 2025
7 $413.7M
Q4 2024 13F
Filed Feb 14, 2025
8 $592.4M
Q3 2024 13F
Filed Nov 14, 2024
7 $582.3M
Q2 2024 13F
Filed Aug 8, 2024
7 $678.1M
Q1 2024 13F
Filed May 3, 2024
6 $707.3M
Q4 2023 13F
Filed Mar 7, 2024
6 $339.4M

Top 15 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 BRVE BRAVEHEART BIO INC $440.9M 41.57%
2 NAMS NEWAMSTERDAM PHARMA COMPANY $206.5M 19.47%
3 KRSA KORSANA BIOSCIENCES INC $70.1M 6.61%
4 VOR VOR BIOPHARMA INC $65.0M 6.13%
5 DYN DYNE THERAPEUTICS INC $57.8M 5.45%
6 GLTO DAMORA THERAPEUTICS INC $51.9M 4.9%
7 MPLT MAPLIGHT THERAPEUTICS INC $45.1M 4.25%
8 AURA AURA BIOSCIENCES INC $33.0M 3.11%
9 CBIO CRESCENT BIOPHARMA INC. $29.5M 2.78%
10 REPL REPLIMUNE GROUP INC $22.8M 2.15%
11 ENGN ENGENE HOLDINGS INC $19.3M 1.82%
12 BCYC BICYCLE THERAPEUTICS PLC $12.8M 1.2%
13 TARS TARSUS PHARMACEUTICALS INC $5.0M 0.47%
14 ENGNW ENGENE HOLDINGS INC $575.6K 0.05%
15 LSTA LISATA THERAPEUTICS INC $428.4K 0.04%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings